Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00449111 |
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_005 |
Study First Received: | March 16, 2007 |
Last Updated: | March 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00449111 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Angiotensin II Type 1 Receptor Blockers Losartan Essential Hypertension Sodium Chloride Symporter Inhibitors Diuretics Vascular Diseases |
Anti-Arrhythmia Agents Cardiovascular Agents Angiotensin II Antihypertensive Agents Hydrochlorothiazide Hypertension |
Losartan Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents Antihypertensive Agents Hydrochlorothiazide |
Pharmacologic Actions Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Anti-Arrhythmia Agents Hypertension |